TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06392945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive Treadmill Walking Training with Rhythmic Auditory Cueing (CTW+RAC) group
Description: Participants in the CTW+RAC group participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. To increase adaptability to rhythmic auditory cueing prior to cognitive treadmill walking training, participants are required to keep stepping on their feet while listening to the auditory cueing using a metronome program (Metronome APP) for 5 minutes of warm up. Then they start walking on a treadmill with a target speed and perform a cognitive task concurrently while listening rhythmic auditory cueing. According to previous research, the target treadmill speed at week 1, week 2, week 3, and week 4 is gradually increased from 90%, 100%, 110%, to 120% baseline walking speed of comfortable walking on the ground. The beat of rhythmic auditory cueing using the Metronome APP on the smartphone is set at 110% of baseline cadence of comfortable walking on the ground based on a previous study in individuals with stroke.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Treadmill Walking Training (CTW) group
Description: Participants in the CTW group will participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. They will start stepping on the ground at comfortable pace for 5 minutes of warm up. Then they will start walking on a treadmill with a target speed and perform a cognitive task concurrently without rhythmic auditory cueing. Same cognitive training and target treadmill speed will be used as the CTW+RAC group during cognitive dual-task treadmill walking. Three cognitive training programs will be the verbal fluency, arithmetic, and visual distinguish tasks. The target treadmill speed will be gradually increased from 90% at week 1, to 100% at week 2, to 110% at week 3, to 120% baseline walking speed of comfortable walking on the 10 meters walk test at week 4.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Walking Training (TW)
Description: Participants in the TW group will participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. They will start stepping on the ground at comfortable pace for 5 minutes of warm up. Then they will start walking on a treadmill with a target speed only, without concurrent performing a cognitive task and no listening rhythmic auditory cueing. Same target treadmill speed will be used as the other two groups during treadmill walking. The target treadmill speed will be gradually increased from 90% at week 1, to 100% at week 2, to 110% at week 3, to 120% baseline walking speed of comfortable walking on the ground.
Study: NCT05944705

Intervention type: DIETARY_SUPPLEMENT
Intervention: Immune Support Supplement
Description: Cannabinoid and co-active emulsion
Study: NCT04774757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Para-aortic lymph node dissection
Description: Para-aortic lymph node dissection was defined as the dissection of para-aortic lymph nodes located below renal vein and above the bifurcation of iliac artery.
Study: NCT05915403

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibromyalgia Impact Questionnaire
Description: diagnostic tests
Study: NCT05364632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention to Increase Physical Activity
Description: The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active. The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting until 90 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own physical activity (PA) data and the behavioural change stage, an individual action plan will be established to increase physical activity. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: The same initial educational program described for the Behavioral Intervention group will be delivered to this group. Each aerobic training session will consist of 45 minutes divided into 5 minutes of warm-up, 35 minutes of aerobic exercise and 5 minutes of cool-down. During physical training, heart rate and level of respiratory distress will be monitored. The intensity of aerobic physical training will be based on the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (LA) and the respiratory compensation point (CRP). The patient may interrupt physical exercise if he presents any clinical symptoms and/or respiratory discomfort, returning as soon as his respiratory condition improves.
Study: NCT04564482

Intervention type: RADIATION
Group type: OTHER
Intervention: CRT
Description: 50 Gy in 2 Gy fractions over 25 working days + capecitabine 1650 mg/m2/d PO

Intervention type: RADIATION
Group type: OTHER
Intervention: SCPRT
Description: 25 Gy in 5 Gy fractions over 5 working days

Intervention type: RADIATION
Group type: OTHER
Intervention: CROSS Protocol
Description: 41.4 Gy in 1.8 Gy fractions over 23 working days + carboplatin AUC of 2 mg/ml/min + paclitaxel 50 mg/m2 IV Q1W

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PD-L1 PET
Description: 10 mg atezolizumab IV followed by 37 MBq 89Zr-atezolizumab IV. PET imaging will be done before neoadjuvant CRT/SCPRT (day 0) and between day 10-14 during CRT/SCPRT.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PD-L1 PET
Description: 10 mg atezolizumab IV followed by 37 MBq 89Zr-atezolizumab IV. PET imaging will be done before neoadjuvant CRT/SCPRT (day 0) and between day 10-14 during CRT/SCPRT.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PD-L1 PET
Description: 10 mg atezolizumab IV followed by 37 MBq 89Zr-atezolizumab IV. PET imaging will be done before neoadjuvant CRT/SCPRT (day 0) and between day 10-14 during CRT/SCPRT.
Study: NCT05754008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AURORA Care Strategy
Description: Participants will be invited to partake in three telemedicine visits with the care navigator during the months following diagnosis. The visits center around proactive and tailored T2D self-management support.
Study: NCT04963491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized TKA prosthesis
Description: TKA prosthesis that is designed and manufactured according to the patient's knee joint anatomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer NexGen prostheses
Description: Commercial products used on a large scale
Study: NCT05577845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron
Description: Ramosetron, 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Ramosetron, 4 weeks
Study: NCT04225663

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Meditation
Description: Participants will meditate in response to the guidance provided by a trained meditation coach in person.
Study: NCT06074588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: 4 mg/kg of MK-sacituzumab tirumotecan by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m\^2 of docetaxel by IV Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m\^2 of pemetrexed by IV infusion
Study: NCT06056297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavorixafor
Description: Mavorixafor will be administered per schedule specified in the arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered per schedule specified in the arm description.
Study: NCT05703516

Intervention type: OTHER
Intervention: Capmatinib
Description: There is no treatment allocation. Capmatinib will be prescribed by the physician as per locally approved label. Treatment duration depends on the decision of treating physician. No drug will be dispensed from Novartis
Study: NCT05954325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunoadsorption vs. sham immunoadsorption
Description: 5 treatments within 14 days

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Immunoadsorption vs. sham immunoadsorption
Description: 5 treatments within 14 days
Study: NCT05442866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality experience for 10 minutes
Description: Each 10-minute VR session will be self-administered (by each participant) using the Facebook (Facebook Inc., Menlo Park, CA) Meta Quest 2 VR and Touch controllers. This equipment was selected because it is portable, has built in audio, and has clear graphics at a lower price than VR setups that require a computer to generate graphics. The headset has an optional eyeglass spacer to allow participants to wear corrective eyeglasses during the VR session if appropriate. The hand controllers facilitate immersive, interactive VR experiences. The VR software, Nature Treks VR application (https://naturetreksvr.com) that features ten non-violent, nature-based experiences in peaceful environments (e.g. forest, river, beach, etc.) that can be played in a seated or fixed position.
Study: NCT06039982

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04882332

Intervention type: OTHER
Intervention: sampling for diabetes control parameters
Description: Intravenous blood withdrawal for a sample of fasting blood glucose (FBG), 2 hr postprandial blood glucose (2 hr -PPG), fasting lipids {total cholesterol (TC), triglycerides (TAG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)}, glycosylated hemoglobin (Hb A1c) ,fasting insulin level and Vitamin B 12 levels

Intervention type: OTHER
Intervention: Sampling for vitamin B12 level
Description: Intravenous blood sampling for a sample of vitamin B12 level
Study: NCT05165056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intimleds
Description: INTIMILEDS® is a photobiomodulation device designed for intravaginal use. It's design permits an irradiation of the whole vaginal wall, the vulva, and the cervix, with a constant intensity.
Study: NCT06495905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transbronchoscopic interventional debridement
Description: 1. combination drug therapy：liposomal amphotericin B + posaconazole or Isavuconazole：3-5mg/kg/day+ Posaconazole 300 mg once daily; target blood trough concentration is \>1ug/mL; if posaconazole is unavailable, Isavuconazole 200 mg once daily may be an alternative.~2. transbronchoscopic local precision infusion of amphotericin B: Maximum dose not more than 30mg per session~3. transoral nebulized inhalation of amphotericin B：amphotericin B 10mg + 5ml of sterilized water for injection, inhalation 2/day.~4)transbronchoscopic interventional debridement
Study: NCT05486637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perception of acoustic cues to emotion
Description: Using novel methodologies and stimuli comprising both controlled laboratory recordings and materials culled from databases of ecologically valid speech emotions (e.g., from publicly available podcasts), the team aims to collect perceptual data to build a statistical model to test the hypothesis that experience-based changes in emotion identification by pediatric and adult CI recipients is mediated by improvements in cue-optimization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Production of acoustic cues to emotion
Description: The team will acoustically analyze vocal emotion productions by participants, quantify acoustic features of spoken emotions, and obtain behavioral measures of how well normally hearing listeners can identify those emotions.
Study: NCT05267366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed
Description: PD-1 inhibitor (pembrolizumab) 200mg iv, d1; bevzcizumab 15mg/kg, iv, d1; Carboplatin 5/AUC or Cisplatin 75mg/m2 iv d1; Pemtrexed 500mg/m2 iv, d1; every 21 days a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed
Description: PD-1 inhibitor (pembrolizumab) 200mg iv, d1; bevzcizumab 15mg/kg, iv, d1; Carboplatin 5/AUC or Cisplatin 75mg/m2 iv d1; Pemtrexed 500mg/m2 iv, d1; every 21 days a cycle.
Study: NCT06522204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: %5 Dextrose
Description: All the patients will receive oral 3mL/kg 5%Dextrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: %5 Dextrose
Description: All the patients will receive oral 3mL/kg 5%Dextrose
Study: NCT04796961

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation Intervention
Description: The implementation intervention involves training, coaching, expert consultation, organizational strategy meetings.
Study: NCT05470803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AstraZeneca/Fiocruz
Description: 4th dose of SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AstraZeneca/Fiocruz
Description: 4th dose of SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AstraZeneca/Fiocruz
Description: 4th dose of SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer/Wyeth
Description: 4th dose of SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer/Wyeth
Description: 4th dose of SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer/Wyeth
Description: 4th dose of SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clover SCB-2019
Description: 4th dose of SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clover SCB-2019
Description: 4th dose of SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clover SCB-2019
Description: 4th dose of SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clover SCB-2019
Description: 4th dose of SARS-CoV-2 vaccine
Study: NCT04785456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TBS
Description: MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS
Description: MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
Study: NCT05039190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HBM9161 Injection (680mg)
Description: HBM9161 Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Injection
Study: NCT04272515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: collection of blood sample for preparation of DNA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy sampling
Description: preparation of primary cultures of dermal fibroblasts from skin biopsy sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: explanted liver of BA patients sampling
Description: cryoconservation of liver tissue for molecular analyses
Study: NCT05728385

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified Specific carbohydrate diet for 3 months
Description: All children at the start of the study will be subjected to:~1. Full history taking including demographic and medical history~2. Full nutritional assessment including: Through clinical examination for any signs of vitamins and mineral deficiency, with full chest examination.~3. Laboratory tests: Complete blood picture with differential white blood cells, and Serum IgE level~4. At the beginning of the study and at the end~   1. The patients will be assessed using the childhood-asthma control test (C-ACT) as a subjective method~  2. Pulmonary function tests will be performed using spirometry (Spirostik, Geratherm) that includes Forced vital capacity (FVC), forced expiratory volume in the first second of FVC (FEV1), and FEV1/FVC.~  3. Anthropometric measurements: Weight, Height, and Body mass index (BMI). All measures will be plotted on specific percentile curves for age and Z score
Study: NCT05431166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Yoga at First 8 weeks
Description: 1 hour per week of virtual yoga delivered by an active movement therapist at the VA during the first 8 weeks of the study

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Yoga at Second 8 weeks
Description: 1 hour per week of virtual yoga delivered by an active movement therapist at the VA during the second 8 weeks of the study
Study: NCT05037110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: For 12 weeks, do 150 minutes of moderate physical activity per week and wear a smart watch to monitor this physical activity goal. This is done remotely. Then, every two weeks, attend a remote individual meeting with a kinesiologist using a secured application (15 minutes each). Each online meeting will contain the following steps: 1) Review of health and activities recorded by the activity watch/app provided to the participant; 2) Discussion on how to reach/maintain the physical activity goal in the coming weeks according to individual health status, facilitators and barriers; 3) Elaboration of the next 2-week action plan.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smell training
Description: For 12 weeks, morning and evening, smell four odors namely eucalyptol, phenyl ethanol, citronellal, and eugenol, for a total of five minutes per session. For each smell training session, complete a short, online survey regarding the pleasantness and intensity of the smell. This is done remotely. Then, every two weeks, attend a remote individual meeting with a research professional using secured application (15 minutes each). Each online meeting will contain the following steps: 1) Review of smell training; 2) Discussion on how to reach/maintain the training protocol in the coming weeks according to individual health status, facilitators and barriers; 3) Elaboration of the next 2-week action plan.
Study: NCT06195020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metaverse
Description: The research consists of two stages (preparation and implementation). In the first stage of the research, the educational material planned to be used in the education of parents (video of navigation in the metaverse) will be developed in the form of modules. The topics in the training materials to be developed are listed below.~Module 1: Information about Epilepsy (What is epilepsy?, What are the causes of epilepsy? Module 2 Diagnostic Methods in Epilepsy (Neurological examination, blood tests, electroencephalogram, screening tests 3rd Module Treatment of Epilepsy (Things to consider in patients receiving antiepileptic drug therapy) Module 4: First Aid in Epilepsy (first aid in seizures with convulsions, first aid in seizures without convulsions) Module 5: Life with Epilepsy (Epilepsy and school, epilepsy and career choice, epilepsy and home safety, epilepsy and exercise, epilepsy and healthy nutrition, epilepsy and sleep) The intervention will last 3 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyclinic information
Description: This group will be informed only at the outpatient clinic. The intervention will last 3 months.
Study: NCT05956106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black Mulberry Fruit Powder
Description: Anthocyanin plays a major role in preventing symptoms of metabolic syndrome.
Study: NCT04743557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYN101
Description: DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 pre-mRNA
Study: NCT05086445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT05812989

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Engage Coaching
Description: Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Engage Coaching
Description: Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Connect for Caregivers
Description: Participants will complete an individual session with a coach who will use a digitized prioritization tool to help identify goals and an action plan for social connectedness.
Study: NCT05872087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulised Dexmeditomidine
Description: premedication by dexmeditomidine 3mcg/kg in children undergoing lower abdominal surgeries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulised Midazolam
Description: premedication by nebulised midazolam 0.3mg/kg in children undergoing lower abdominal surgeries
Study: NCT06403085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study group
Description: Rhythmic Stabilization, Limb Matching, Double and Single Arm Balance, Balance with Ball and Weight Transfer will be performed for 8 weeks.